Related Experiment Video
Updated: Sep 1, 2025

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
Published on: February 24, 2023
Novel Clinical Trial Designs in Neuro-Oncology
Anurag Saraf1,2, Lorenzo Trippa3, Rifaquat Rahman4
1Harvard Radiation Oncology Program, Boston, MA, USA.
Abstract:
Scientific and technologic advances have led to a boon of candidate therapeutics for patients with malignancies of the central nervous system. The path from drug development to clinical use has generally followed a regimented order of sequential clinical trial phases. The recent increase in novel therapies, however, has strained the regulatory process and unearthed limitations of the current system, including significant cost, prolonged development time, and difficulties in testing therapies for rarer tumors. Novel clinical trial designs have emerged to increase efficiencies in clinical trial conduct to better evaluate and bring impactful drugs to patients in a timely manner. In order to better capture meaningful benefits for brain tumor patients, new endpoints to complement or replace traditional endpoints are also an increasingly important consideration. This review will explore the current challenges in the current clinical trial landscape and discuss novel clinical trial concepts, including consideration of limitations and risks of novel trial designs, within the context of neuro-oncology.
Insights
Novel clinical trial designs are needed to accelerate the evaluation of new central nervous system (CNS) cancer therapies. This review discusses challenges and innovative approaches for neuro-oncology drug development.
Area of Science:
- Neuro-oncology
- Clinical trial design
- Drug development
Background:
- Advances in science and technology have produced many new therapies for central nervous system (CNS) malignancies.
- The traditional sequential clinical trial phases are insufficient for novel therapies due to cost, time, and challenges with rare tumors.
Purpose of the Study:
- To explore current challenges in neuro-oncology clinical trials.
- To discuss novel clinical trial designs and endpoints for brain tumor therapeutics.
- To consider the limitations and risks of innovative trial designs.
Main Methods:
- Review of current literature on clinical trial design in neuro-oncology.
- Analysis of challenges in drug development for CNS malignancies.
- Discussion of novel trial concepts and endpoints.
Main Results:
- The current clinical trial system faces significant challenges in evaluating novel CNS therapeutics.
- Novel trial designs and endpoints are emerging to improve efficiency and patient benefit.
- Rarer tumors and complex therapies necessitate adaptive and innovative trial strategies.
Conclusions:
- Innovative clinical trial designs are crucial for timely and efficient evaluation of neuro-oncology drugs.
- Adapting trial methodologies and endpoints is essential to meet the needs of brain tumor patients.
- Careful consideration of risks and limitations is necessary when implementing novel trial designs.
More Related Videos
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
11:09Establishing Intracranial Brain Tumor Xenografts With Subsequent Analysis of Tumor Growth and Response to Therapy using Bioluminescence Imaging
Published on: July 13, 2010
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Treatment Resistant Cancers
Preclinical Development: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...